Last week, the World Health Organization (WHO) announced that it signed a memorandum of understanding with the International Generic and Biosimilar Medicines Association (IGBA) to promote access to generics and biosimilars.  According to the WHO press release, the memorandum underscores “the importance of generic and biosimilar medicines to increasing access to affordable, quality treatment.”  The press release goes on to say that that the memorandum “will facilitate cooperation between the two organizations to reduce the burden of clinical trials for biosimilars, speeding up registration and increasing access.”